Browse the evidence

Females have a higher percentage of body fat and fat mass, and lower fat-free mass compared to males across all age groups, but the trajectory of body composition change with age is similar between sexes.

Women naturally carry more fat and less muscle than men, which lowers their baseline calorie needs. However, as you age, your body composition changes (losing muscle, gaining fat) in a pattern very similar to men. Focus on strength training to preserve muscle mass; this is the most effective way to counteract the age-related drop in energy expenditure for both sexes.

Thyroid dysfunction and structural changes caused by overnutrition are largely reversible through weight loss and return to a normal diet.

If you have obesity-related thyroid issues, know that they are likely reversible. Losing weight through diet and lifestyle changes can restore normal thyroid function and hormone levels.

Tirzepatide demonstrates high clinical efficacy but has a higher Incremental Cost-Effectiveness Ratio (ICER), making its cost-effectiveness context-dependent.

Tirzepatide is a highly effective once-weekly peptide for weight loss, but its higher cost-effectiveness ratio means it may not be the most economical choice in all healthcare settings compared to Semaglutide.

Phentermine-topiramate (Qysmia) offers acceptable cost-effectiveness, particularly in low-resource settings, making it a practical alternative to more expensive drugs.

For patients in low-resource settings, Phentermine-topiramate (Qysmia) is a cost-effective and practical alternative to more expensive obesity medications.

Orlistat is an affordable option with lower effectiveness, making it a practical alternative in resource-limited settings.

Orlistat (120 mg three times daily) is an affordable option for weight loss, but it has lower effectiveness compared to newer drugs like Semaglutide, making it a practical choice primarily in resource-limited settings.

Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.

For patients with obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide (15 mg weekly) has been shown to significantly reduce the risk of heart failure hospitalizations and cardiovascular death. It also improves heart structure and quality of life. This makes it a valuable option for this specific population, in addition to its benefits for diabetes and weight loss.

Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).

Tirzepatide (Zepbound) is now approved for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It significantly reduces the number of breathing interruptions per hour (AHI) by 50-60%. This may lead to less daytime sleepiness and potentially reduced reliance on CPAP machines, though long-term data is still emerging.

Multidisciplinary therapy reduces inflammatory biomarkers (CRP, IL-6, TNF-alpha) and improves the leptin/adiponectin ratio in adults with obesity.

Reducing inflammation is a key benefit of weight loss therapy. By losing weight through a multidisciplinary approach, you can lower levels of inflammatory markers like CRP and IL-6, and improve the balance of hormones like leptin and adiponectin, which protects against cardiovascular disease and other complications.

Bariatric surgery results in greater weight loss and improvement in cardiac troponins compared to intensive lifestyle intervention alone in patients with severe obesity.

For severe obesity, bariatric surgery is more effective than lifestyle changes alone for weight loss and improving heart health markers like cardiac troponins. It is considered when other treatments fail.

Pharmacological interventions, specifically GLP-1 receptor agonists and SGLT2 inhibitors, reduce epicardial adipose tissue (EAT) volume and improve cardiovascular outcomes, often independent of weight loss.

If you have T2DM, obesity, or heart failure, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs can reduce the fat around your heart and improve your heart's function, sometimes even without significant weight loss.

In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.

If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.

Mandibular advancement devices (MADs) provide symptom relief comparable to CPAP in mild-to-moderate OSA primarily due to superior long-term adherence, despite CPAP's superior objective efficacy in reducing AHI.

If you have mild-to-moderate sleep apnea and struggle with CPAP, ask about a mandibular advancement device. It might not reduce your apnea events as much as CPAP, but you are more likely to use it every night, which often leads to better overall health outcomes and symptom relief.

GLP-1-based therapies, particularly dual GLP-1/GIP agonists like tirzepatide, produce large, clinically meaningful reductions in AHI and cardiometabolic risk in obesity-associated OSA.

If you have obesity-related sleep apnea, ask your doctor about GLP-1/GIP agonists like tirzepatide. These medications can significantly reduce your apnea severity by reducing weight and metabolic load, offering a systemic treatment option.

Hypoglossal nerve stimulation (HNS) produces substantial, durable improvements in AHI and symptoms with high adherence, supported by randomized trials and real-world data.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask about hypoglossal nerve stimulation (HNS). It is an implanted device that stimulates the tongue to keep the airway open, offering substantial and durable relief for the right candidate.

GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.

If you are obese, ask your doctor about GLP-1 agonists. They can significantly improve your blood pressure, blood sugar, and inflammation levels, reducing your overall risk of heart disease and stroke.

GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.

If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Nutritional interventions (protein, leucine, HMB, creatine) preserve or modestly increase lean mass in sarcopenia but fail to consistently restore muscle strength or physical function when applied in isolation.

Eat enough protein (at least 1.2g per kg of body weight daily) and consider creatine or HMB, but do not expect these supplements to fix your strength or balance on their own. You must combine them with resistance exercise to see functional benefits. Nutrition primes the muscle, but exercise builds the function.

Older adults (>30 years) significantly increase their energy intake from ultra-processed foods (UPFs) on weekends compared to weekdays, whereas younger adults (18-30 years) maintain consistent UPF consumption levels regardless of the day of the week.

If you are over 30, your weekend meals are likely driving your high ultra-processed food intake, whereas your weekday habits are stable. To improve your diet, focus your planning efforts specifically on Friday through Sunday. You do not need to change your weekday routine, as your data shows consistency there. Targeting the weekend window is the highest-yield intervention for this demographic.

Younger adults (18-30 years) consume ultra-processed foods (UPFs) in a continuous 'grazing' pattern throughout the day, with distinct peaks at 8 pm and 1 pm, whereas older adults follow conventional three-meal patterns with an additional morning peak.

If you are under 30, you likely snack on ultra-processed foods throughout the day rather than just at meals. Your intake peaks at 1 pm and 8 pm. To reduce UPF intake, focus on eliminating snacks during these specific hours, particularly the late evening peak, rather than just trying to eat 'less' overall.